The formation of spin-out company Aduro Biopolymers by WaikatoLink Limited, the technology transfer organisation of the University of Waikato, has resulted in a finals place in the Commercial Deal Award in the KiwiNet Research Commercialisation Awards. Winners will be announced at an awards function on 19th June in Auckland.
UPM and students from Helsinki Metropolia University of Applied Sciences are building a Biofore concept car utilising UPM’s innovative biomaterials as main raw material for many parts and components.
Ceram, the international materials technology company, will be holding a free breakfast forum ‘Re-Engineering Materials - Reduce Waste, Ensure Future Raw Materials Supply and Save Money’ on Friday 14 June at ...
Avid Bioservices, Inc., a wholly owned subsidiary of Peregrine Pharmaceuticals, Inc., today announced that its recent success in qualifying an antibody-dependent, cell-mediated cytotoxicity (ADCC) bioassay will be highlighted in a poster presentation at IBC's 23rd International Intensive Symposium Development, Validation and Maintenance of Biological Assays Conference to be held in Seattle, Washington, May 14-16, 2013.
In 2012, more than 3 million people had stents inserted in their coronary arteries. These tiny mesh tubes prop open blood vessels healing from procedures like a balloon angioplasty, which widens arteries blocked by clots or plaque deposits. After about six months, most damaged arteries are healed and stay open on their own. The stent, however, is there for a lifetime.
It's a familiar scenario – a patient receives a medical implant and days later, the body attacks the artificial valve or device, causing complications to an already compromised system.
Some parts of the body, like the liver, can regenerate themselves after damage. But others, such as our nervous system, are considered either irreparable or slow to recover, leaving thousands with a lifetime of pain, limited mobility, or even paralysis.
Researchers have made a significant first step with newly engineered biomaterials for cell transplantation that could help lead to a possible cure for Type 1 diabetes, which affects about 3 million Americans.
Over 20 million people in Europe suffer from osteoarthritis which can lead to extensive damage to the knee and hip cartilage. Stem cells offer a promising way forward but a key challenge has been to design a ‘smart material’ that is biologically effective for cartilage tissue regeneration.
Spherix Incorporated -- an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, today announced the signing of a memorandum of understanding (MOU) with ChromaDex to extend the commercial market for D-tagatose, extend the structure function claims for the GRAS food ingredient, and to optimize a new system of D-tagatose production.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.